Skandinaviska Enskilda Banken (SEB)
JAZZ icon

Skandinaviska Enskilda Banken (SEB)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-51,612
Closed -$6.4M – 725
2018
Q4 		$6.4M Sell
51,612
-1,134
-2% -$168K 0.06% 239
2018
Q3 		$8.87M Buy
+52,746
New +$9.07M 0.07% 206

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s JAZZ Position: Q1 2019 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 51,612 shares — an estimated $6.4M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in JAZZ in Q3 2018 and held it in 2 quarters. The position peaked at $8.87M in Q3 2018. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 51,612 Jazz Pharmaceuticals shares in Q1 2019, an estimated $6.4M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Jazz Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Jazz Pharmaceuticals position peaked at $8.87M in Q3 2018.
  • 427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2019, filed 15 May 2019.